BioPharmSignal logoBioPharmSignal

Biotech News

Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026

Fulgent Genetics, Inc. (FLGT)Fulgent Genetics, Inc.Earnings

EL MONTE, Calif. --(BUSINESS WIRE)--Oct. 15, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2026

Related news

GERNGeron2026-10-21 12:00 EST

Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026

RVMDRevolution Medicines2026-10-21 20:05 EST

Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026

BNTXBioNTech2026-10-20 10:45 EST

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

EXELExelixis2026-10-15 20:05 EST

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

TEVATeva Pharmaceutical Industries2026-09-23 20:45 EST

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

KYMRKymera2026-10-22 20:01 EST

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

ARGXArgenx2026-10-15 05:00 EST

argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026

NRIXNurix Therapeutics2026-10-12 20:05 EST

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

MMSIMerit Medical2026-10-06 20:30 EST

Merit Medical Systems to Announce Third Quarter 2026 Results on October 29, 2026

REGNRegeneron Pharmaceuticals2026-09-24 20:05 EST

Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026

View all latest news

Fulgent Genetics, Inc.

Precision Medicine Business Fulgent Genetics operates a laboratory-services business alongside a therapeutic-development portfolio. The company aims to combine diagnostic capabilities with drug development to become an integrated precision-medicine organization. Laboratory Services Fulgent provides technical laboratory testing and...

Recent company news

FLGTFulgent Genetics, Inc.2026-10-15 20:05 EST

Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026

FLGTFulgent Genetics, Inc.2026-07-30 20:05 EST

Fulgent Reports Second Quarter 2026 Financial Results

FLGTFulgent Genetics, Inc.2026-07-09 20:05 EST

Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

FLGTFulgent Genetics, Inc.2026-06-01 23:00 EST

Fulgent Presents Updated FID-007 Data at ASCO 2026

FLGTFulgent Genetics, Inc.2026-05-21 21:03 EST

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

Stock data

Close
19.99 USD
Market cap
531.09M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States